Antiviral drugs are as important as vaccines in the fight against coronavirus.

!-- webeditor: page title -- April 14, 2020 / -- While many scientists are working on a coronavirus vaccine, others are busy testing antiviral drugs.
vaccines are usually only effective before infection, but antiviral drugs are important because they can treat people who are already infected with COVID-19.
is an overview of the coronavirus antiviral drugs being studied by scientists.
image source: How do antiviral drugs work by targeting replication targets? First, it is important to know that the genomes of plants and animals are made up of DNA, but the genomes of viruses can also be made up of RNA.
this is the case with SARS-CoV-2 coronavirus, which causes COVID-19.
to replicate, RNA viruses need to produce more RNA genomes.
means that antiviral drugs that block RNA genome replication may help treat COVID-19 patients.
these drugs are called RNA polymerase inhibitors.
these types of drugs have succeeded in curing chronic hepatitis C, another disease caused by an RNA virus infection.
but not all viral RNA polymerases are the same, so drugs that are effective against hepatitis C virus may not be effective for human coronavirus.
Favilavir is an RNA polymerase inhibitor drug that scientists are currently experimenting with against coronavirus.
successful antiviral drug strategy to stop the spread of the virus is to use unreal copies of functional "likens", which are essential components of the viral RNA genome.
the presence of similars in the virus genome hinders viral polymerases, which means that viruses cannot replicate their RNA.
such drugs as axilovvir, libavirin and azithroside (AZT).
, this coronavirus is a bit tricky because it "verifies" the authenticity of its RNA genome.
, it can determine that similar objects are untrue and remove them.
this prevents the effectiveness of certain antiviral drugs such as libavirin.
, the coronavirus's ability to correct did not prevent a similar drug, Redsyvir.
, Redsyvir effectively blocked the replication of coronaviruses and provided a promising drug option for PATIENTs with COVID-19.
redsivir is also effective against other RNA viruses, including Ebola, coronavirus SARS and Middle East Respiratory Syndrome (MERS).
scientists are currently evaluating Redsiway in clinical trials.
time will tell if Redsyve is effective for PATIENTs with COVID-19.
but doctors are already considering how best to use the drug for best results and whether it should be used in union with other drugs or as a single drug.
other proven antiviral drugs many RNA viruses produce a single "polyprotein" that is then broken down into separate proteins by an enzyme called protease.
any molecule that inhibits these proteases is likely to become an antiviral drug.
Protease inhibitors are effective drugs for the treatment of human immunodeficiency virus (HIV) and hepatitis C viruses.
and litonave are a combined protease inhibitor (Kaletra) that inhibits coronaviruses in human cells.
Kaletra has been used in South Korea to treat a COVID-19 patient, but a larger trial found that its effects were not convincing.
reasons for these differences are not yet clear, and more research is clearly needed.
any antiviral drug, the sooner the patient is infected, the better.
because viruses replicate so quickly that they can produce dozens to hundreds of new infectious viruses.
cytokine storms in respiratory infections caused by influenza or SARS-CoV-2 virus, clinically serious infections include so-called "cytokine storms".
, a strong immune response leads to high levels of inflammatory media: cytokines and coercion factors.
these molecules recruit inflammatory cells to virally infected areas, such as the lungs of patients with COVID-19.
these cytokines and cells then fight viral infections, their presence also hinders the exchange of oxygen to some extent.
are currently considering additional therapies that limit the inflammatory response to some extent by blocking the effects of certain cytokines and coercion factors.
these additional treatments include antibody-based drugs, such as tocilizumab, which blocks the lecilizumab of the lecirogen-6 cytokine receptor, or leronlimab, which blocks the chloride receptor CCR5.
when cytokine and tendonor subjects are blocked, the high levels of cytokines or coercion factors are less important because their effects are significantly minimized.
: The good news is that antibody-based drugs have few side effects and have been shown to be effective against chronic inflammatory diseases in many humans.
, expanding the use of these drugs in COVID-19 patients is an attractive possibility.
, although this will require careful dosages, and these drugs will need to be used in 2 with antiviral drugs.
antimalarial drug chloroquine, a well-known antimalarial drug, has also attracted attention.
a study to test it with the broad-spectrum antibiotic azithromycin.
in this small study, some COVID-19 patients recovered, others died (despite the use of chloroquine), and some patients stopped treatment for a variety of reasons -- including the severity of their symptoms.
, however, there is interest in how chloroquine and azithromycin treat coronavirus.
chloroquine is antiviral and is currently used to treat autoimmune diseases because it also has anti-inflammatory properties.
is an antibiotic used to treat bacterial infections, but it also exhibits antiviral activity, including fighting rhinoviruses that cause the common cold.
may need to be treated early after infection to best combat coronavirus.
the World Health Organization announced a global clinical trial program to test possible COVID-19 therapies, including Redsivir, Kaletra, chloroquine and certain antiviral cytokines.
increasing number of coronavirus patients worldwide means that, in addition to vaccine development, emphasis must be placed on finding effective antiviral drugs to treat seriously ill patients who are already infected with SARS-CoV-2.
() !--/ewebeditor: page-- !--ewebeditor: page title"--reference: 1. In the fight against coronavirus, antivirals are as important as a vaccine (2) Antiviral Activity of Chloroquine against Human Coronavirus OC43 Oc43 Application in Update Mice (3) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomed clinical trial Therapeutic Antibody-Based Drugs in The Treatment of Humane A Disorders 5 A Trial of Lopinavir-Ritonavir in Adults Appred with Severe Covid-19(6)11 Studies found for: remdesivir !--/ewebeditor:page--page.